We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Razuprotafib

News List

Quantum Leap Healthcare Discontinues Razuprotafib I-SPY COVID Trial americanpharmaceuticalreview
March 11, 2021
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio drug, razuprotafib.
Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients prnewswire
September 03, 2020
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced dosing of the first patient with razuprotafib in the I-SPY COVID Trial (NCT04488081), a phase 2 platform trial aimed at improving treatment of acute ...
Aerpio, Quantum Leap Select Razuprotafib as Potential Treatment for COVID-19 ARDS americanpharmaceuticalreview
June 02, 2020
Aerpio Pharmaceuticals and Quantum Leap Healthcare Collaborative™ announced an agreement has been reached to evaluate razuprotafib in a new randomized ...